Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements - Additional Information (Detail)

v3.21.2
Collaboration and License Agreements - Additional Information (Detail) - Janssen Pharmaceutical NV [Member] - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Accrued royalties $ 0 $ 0
Maximum [Member]    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Percentage of royalty on net sales 8.00%